BioTech, Health Policy, Medicare and Patient Experience

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

BioTech

Health Policy

Medicare

Patient Experience

In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned

Health Populi

JANUARY 18, 2019

As the Harvard Chan-POLITICO study points out, prescription drug costs are top-of-mind for health consumers in America. First, a Wall Street Journal profile of Bluebird Bio , a biotech firm that plans to sell gene-replacement therapy extending annual payments to patients based on whether the drug is effective.

BioTech

BioTech Medicare Medical Billing Patient Experience

Most Americans Across Party ID Favor U.S. Government Negotiation to Lower Rx Drug Costs

Health Populi

MARCH 6, 2019

is prescription drug prices — that they’re too high, that the Federal government should negotiate to lower costs for Medicare enrollees, and that out-of-pocket costs for drugs should be limited. One of the only issues bringing people together in the U.S.

Pharmaceuticals

Pharmaceuticals Life Science Medicare BioTech

Connected Health Pulse

In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned

Most Americans Across Party ID Favor U.S. Government Negotiation to Lower Rx Drug Costs

Stay Connected